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In spite of the progress in the treatment of lysosomal 
storage  diseases  (LSDs),  in  some  of  these  disorders 
the  available  therapies  show  limited  efficacy  and  a 
need exists to identify novel therapeutic strategies. We 
studied  the  combination  of  enzyme  replacement  and 
enzyme enhancement by pharmacological chaperones 
in Pompe disease (PD), a metabolic myopathy caused 
by the deficiency of the lysosomal acid α-glucosidase. 
We showed that coincubation of Pompe fibroblasts with 
recombinant human α-glucosidase and the chaperone 
  N-butyldeoxynojirimycin  (NB-DNJ)  resulted  in  more 
efficient correction of enzyme activity. The chaperone 
improved α-glucosidase delivery to lysosomes, enhanced 
enzyme  maturation,  and  increased  enzyme  stability. 
Improved enzyme correction was also found in vivo in 
a mouse model of PD treated with coadministration of 
single  infusions  of  recombinant  human  α-glucosidase 
and oral NB-DNJ. The enhancing effect of chaperones 
on  recombinant  enzymes  was  also  observed  in  fibro-
blasts  from  another  lysosomal  disease,  Fabry  disease, 
treated with recombinant α-galactosidase A and the spe-
cific chaperone 1-deoxygalactonojirimycin (DGJ). These 
results have important clinical implications, as they dem-
onstrate synergy between pharmacological chaperones 
and enzyme replacement. A synergistic effect of these 
treatments  may  result  particularly  useful  in  patients 
responding poorly to therapy and in tissues in which 
  sufficient enzyme levels are difficult to obtain.
Received 4 February 2009; accepted 20 February 2009; published online 
17 March 2009. doi:10.1038/mt.2009.53
IntroductIon
During the past two decades, impressive progress has been made 
in the treatment of lysosomal storage diseases (LSDs), a group of 
genetic disorders caused by defects in any aspect of lysosomal biol-
ogy and characterized by the storage of a variety of undegraded 
molecules in the endosomal/lysosomal compartment.1,2
Different therapeutic approaches have been developed, includ-
ing hematopoietic stem cell transplantation,3 enzyme replacement 
therapy  (ERT),4  substrate  reduction  therapy,5  and  enzyme 
enhancement  therapy  (EET)  by  pharmacological  chaperones.6 
With a few exceptions,7–9 published guidelines for the treatment 
of LSDs do not recommend protocols based on the combined use 
of these therapies.
ERT, a major breakthrough in the treatment of LSDs, was suc-
cessfully translated into the clinical use for some of the most prev-
alent LSDs, and is currently under study for further applications 
in other disorders. ERT is based on the concept that recombinant 
lysosomal hydrolases, mostly enzyme precursors, manufactured 
on a large scale in eukaryotic cell systems, by interacting with the 
mannose-6-phosphate or mannose receptors are internalized by 
cells and tissues through the endocytic pathway and targeted to 
lysosomes. In the lysosomal compartment, they are activated and 
can replace the function of the mutated defective hydrolases.
Although ERT proved to be highly beneficial in some diseases, 
or in subsets of patients with specific diseases, a number of prob-
lems related to its efficacy remain unsolved, such as bioavailability 
of recombinant enzymes, the existence of “sanctuaries” in which 
corrective enzyme levels are difficult to achieve, and the presence 
of cellular abnormalities triggered by storage which interfere with 
ERT efficacy.1
Pompe disease (PD, glycogenosis type II) is a prototype of LSD 
in which several of these problems, related to ERT efficacy, were 
encountered both in clinical and in laboratory studies.
PD is a metabolic disorder, with an estimated incidence of 
1:40,000 live births, caused by defective activity of the lysosomal 
hydrolase acid α-glucosidase (GAA, acid maltase).10,11 GAA defi-
ciency results in generalized intralysosomal glycogen storage, that 
is responsible for extensive damage of muscles, through mecha-
nisms that still remain partially understood and probably involve a 
derangement of autophagy.12,13 As a consequence of the prominent 
muscular involvement, the clinical picture of PD shares   common 
features with that of neuromuscular disorders.11 The disease spec-
trum is extremely wide and ranges from a “classic” infantile-on-
set PD with a severe hypertrophic cardiomyopathy and rapidly 
  progressive course,14 to the early or childhood-onset “interme-
diate”  phenotypes  and  the  attenuated  juvenile  and    adult-onset 
forms, in which cardiac muscle is spared and muscle weakness is 
the   primary symptom.11,15,16
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Although  ERT  with  recombinant  human  GAA  (rhGAA), 
available  for  PD  since  2000,17  showed  remarkable  success  in 
reverting  cardiac  muscle  pathology  and  extending  life  expec-
tancy in   infantile-onset patients, a number of reports suggest that 
correction of skeletal muscle disease is particularly challenging 
and that not all patients respond equally well to treatment.11,18–21 
These limitations are, in part, due to the insufficient targeting and 
uptake of the rhGAA used for ERT in muscle, resulting in modest 
increases of tissue enzyme activity22 and to cellular abnormalities 
that cause aberrant trafficking of the recombinant enzyme.23,24 For 
these reasons, a need exists for alternative strategies to the treat-
ment of PD, based on different approaches and rationale.
An approach that has recently attracted much interest for the 
treatment of LSDs is EET with small molecule pharmacological 
chaperones. EET is based on the concept that loss-of-function dis-
eases are often due to missense mutations causing misfolding and 
degradation of catalytically competent enzyme proteins.6,25 Partial 
rescue of enzyme activity may be obtained by active site–directed 
competitive inhibitors, that can improve folding and stability of 
mutated proteins with altered conformations by acting as folding 
templates. The use of pharmacological chaperones was first pro-
posed in Fabry disease26 and has been investigated in a restricted 
number of other LSDs.27–31 Two in vitro studies provided the proof 
of principle that EET may be extended to PD.32,33 In both studies, 
two imino sugars, 1-deoxynojirimycin and its alkylated derivative 
N-butyldeoxynojirimycin (NB-DNJ) led to enhanced GAA activ-
ity in fibroblasts from PD patient carrying specific mutations of 
the GAA gene.
It is commonly assumed that EET by pharmacological chap-
erones should be restricted to the rescue of mutant proteins with 
altered conformations. However, there are reasons to speculate 
that pharmacological chaperones also have an effect on wild-type 
recombinant enzymes.
First, it has been shown that active-site inhibitors induce confor-
mational stabilization and protect wild-type enzymes from physical 
agents, such as pH and thermal inactivation.34 Second, it has been 
demonstrated in vitro, in PD fibroblasts,24 and in vivo, in muscle cells 
of a PD mouse model23 that a fraction of the rhGAA provided as ERT 
is mistargeted and is thus ineffective. It is possible that delivery to 
inappropriate cellular compartments exposes recombinant enzymes 
to degradation and that interaction with pharmacological chaper-
ones may enhance, at least in part, enzyme stability. A recent article, 
showing that preincubation of recombinant β-glucocerebrosidase 
with isofagomine results in improved uptake and stability35 in cells 
from  Gaucher  disease,  apparently  supports  the  hypothesis  that 
chaperones may increase the efficacy of ERT.
Here, we report that the pharmacological chaperone NB-DNJ 
improves effectiveness of rhGAA in PD cells. Improving the sta-
bility and efficacy of ERT in PD has important clinical implica-
tions, particularly in patients responding poorly to therapy and in 
tissues in which sufficient enzyme levels are difficult to obtain. We 
observed that coadministration of NB-DNJ and rhGAA in cul-
tured fibroblasts from PD patients with different genotypes and 
phenotypes results in more efficient enzyme correction. NB-DNJ 
also improved delivery of rhGAA to lysosomes, enhanced rhGAA 
maturation into the active mature polypeptides and resulted in 
prolonged persistence of the enzyme within cells.
results
We studied the effects of the pharmacological chaperone NB-DNJ 
on the efficacy of ERT in cell lines derived from PD patients. 
Information about patients’ phenotype, genotype, and GAA resid-
ual activity is reported in Supplementary Table S1.
nB-dnJ enhances correction of GAA  
activity by rhGAA
We incubated PD fibroblasts with 50 µmol/l rhGAA in the pres-
ence or in the absence of 20 µmol/l NB-DNJ. The chaperone con-
centration of 20 µmol/l has been previously shown to be effective 
in rescuing mutated GAA.33 This concentration is the range that 
can be achieved in patients with Gaucher disease treated with 
this drug as a substrate reducing agent for its inhibitory effect on 
ceramide glucosyltransferase.36 After 24 hours, the cells were har-
vested and the correction of enzyme activity was analyzed.
In all PD cell lines coadministration of rhGAA and NB-DNJ 
resulted in more efficient correction of enzyme activity (Figure 1a) 
as compared to the activity obtained in cells incubated with the 
recombinant enzyme alone. Intracellular GAA activity increased 
linearly  at  different  rhGAA  concentrations  (0.5,  5 µmol/l) 
(not shown).
The effect of NB-DNJ was not due to enhancement of the 
endogenous GAA residual activity, as improved correction was 
seen in all PD cells tested, including cells from patients carrying 
mutations  that  are  nonresponsive  to  pharmacological  chaper-
ones (PD2 and PD5). In addition, the increase of GAA activity in 
chaperone-responsive cells, after coadministration of rhGAA and 
NB-DNJ, was much higher than that observed after incubation 
with the chaperone alone.33,32 Also, studies with AlexaFluor546-
labeled rhGAA in PD1 and PD2 fibroblasts showed increased flu-
orescence intensity in cells incubated with NB-DNJ (Figure 1b,c). 
Because  by  this  approach  only  the  exogenous  rhGAA  can  be 
detected,  these  results  confirm  that  the  effect  of  NB-DNJ  on 
enzyme activity was not due to the enhancement of the endog-
enous mutated GAA.
The  enhancing  effect  was  only  seen  after  coincubation  of 
rhGAA and NB-DNJ. Pre-incubation of rhGAA with the chaper-
one before being added to the medium did not result in enhanced 
correction of GAA.
nB-dnJ improves rhGAA delivery to lysosomes, 
maturation, and stability
To investigate the mechanisms leading to the enhanced GAA cor-
rection, we studied rhGAA trafficking in two of the PD cell lines 
(PD1 and PD2). We have previously demonstrated that these PD 
cell lines show reduced availability of cation-independent man-
nose 6-phosphate receptor at the plasma membrane and impaired 
rhGAA uptake.24 In addition, PD fibroblasts showed inefficient 
delivery of the internalized enzyme to lysosomes (not shown). 
Lysosomal  targeting  is  important  because  rhGAA  is  provided 
as the 110 kd GAA precursor that, upon reaching the late endo-
somal/lysosomal compartment, is proteolytically processed, after 
8–16 hours into the active polypeptides of 76 and 70 kd, through 
an intermediate molecular form of 95 kd.37 Improving the target-
ing of rhGAA to lysosomes is therefore crucial for correction of 
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We studied the intracellular distribution of AlexaFluor546-
rhGAA in PD fibroblasts in the absence or in the presence of 
20 µmol/l NB-DNJ. PD cells were incubated for 8 hours; then they 
were fixed, stained with an antiserum against the lysosomal marker 
LAMP2, and analyzed using confocal microscopy. PD cells inter-
nalized less rhGAA, as compared to controls (Figure 2a–c) and 
showed abundant LAMP2 signal, delimitating enlarged vesicles, 
a pattern consistent with the staining of a membrane-associated 
lysosomal protein and with the presence of lysosomal storage and 
expansion. In both cell lines, incubation with NB-DNJ improved 
lysosomal targeting, with increased coefficients of rhGAA-LAMP2 
colocalization (Figure 2d).
Consistent with these data were the results of a western blot 
analysis  of  the  GAA  polypeptides.  In  both  PD1  and  PD2  cell 
homogenates  GAA  maturation  into  the  70–76  kd  molecular 
forms was enhanced in the presence of the chaperone (Figure 3a), 
indicating  improved  delivery  to  the  late  endosomal/lysosomal 
compartment.
The improved maturation was also confirmed by studying the 
time-course of GAA correction in PD cells incubated with rhGAA 
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Figure  1  nB-dnJ  improves  correction  of  GAA  activity  by  rhGAA. 
(a) GAA activity in PD fibroblasts. PD fibroblasts were incubated with 
rhGAA in the absence (black bars) or presence (gray bars) of 20 µmol/l 
NB-DNJ for 24 hours. The cells were then harvested, homogenized, and 
the activity of GAA was measured. In all PD cell lines, correction of GAA 
activity was more efficient in the presence of the chaperone. Asterisks 
indicate  statistical  significance  (P  <  0.05).  (b)  Immunofluorescence 
analysis of AlexaFluor546-labeled rhGAA PD1 and PD2 fibroblasts. The 
cells were grown on coverslips, incubated with fluorescent rhGAA for 
4 hours, fixed, and visualized by fluorescence confocal microscopy. (c) In 
NB-DNJ-treated  cells  of  AlexaFluor546-rhGAA  fluorescence  signal  was 
higher, as indicated by the analysis of fluorescence intensity. GAA, acid 
α-glucosidase; NB-DNJ, N-butyldeoxynojirimycin; PD, Pompe disease.
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Figure 2  nB-dnJ improves rhGAA targeting to lysosomes. Confocal 
fluorescence  microscopy  analysis  of  colocalization  of  AlexaFluor546-
labeled rhGAA (red) and the lysosomal marker LAMP2 (green). (a) PD1 
and (b) PD2 fibroblasts untreated (top) and treated with 20 µmol/l NB-DNJ 
(bottom). The cells were incubated with AlexaFluor546-labeled rhGAA 
for 4 and 8 hours. The images represent the results obtained after 4 hours 
of incubation. The right columns in panels a and b show the merged 
images  of  double  staining  of  rhGAA  and  LAMP2.  Magnification  ×63. 
Insets  show  higher  magnification  views.  (c)  Confocal  immunofluores-
cence analysis of rhGAA and LAMP2 in control fibroblasts is shown for 
comparison. (d) Quantitative analysis of rhGAA and LAMP2 colocaliza-
tion. The rate of rhGAA/LAMP2 colocalization was analyzed using the 
LSM 3.2 software (Zeiss). In both PD1 and PD2 fibroblasts, the chaper-
one improved rhGAA localization to lysosomes. GAA, acid α-glucosidase; 
NB-DNJ, N-butyldeoxynojirimycin; PD, Pompe disease.Molecular Therapy  vol. 17 no. 6 june 2009  967
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(Figure  3b).  We  found  that  substantial  enhancement  of  GAA 
  correction  by  NB-DNJ  is  seen  after  8–18  hours  of  incubation 
and that the gap in enzyme correction between cells incubated 
with and without the chaperone becomes progressively wider, as 
increasing amounts of the active molecular forms are generated in 
chaperone-treated cells.
To  study  GAA  stability,  we  incubated  PD  fibroblasts  with 
50 µmol/l rhGAA for 24 hours and then we chased the cells for vari-
able times, up to 30 hours, to analyze the decline of intracellular 
enzyme activity and of GAA polypeptides. In PD1 and PD2 cells, 
rhGAA activity decreased within a few hours after removing rhGAA 
from the medium. When PD cells were incubated with rhGAA in the 
presence of 20 µmol/l NB-DNJ, that was maintained in the medium 
during the chase period, enzyme stability increased (Figure 4a). 
These data were also confirmed by the western blot analysis of GAA, 
showing prolonged persistence of the mature 76 kd GAA polypep-
tide in PD fibroblasts incubated with NB-DNJ (Figure 4b).
nB-dnJ improves correction of GAA activity in vivo
A major therapeutic goal in PD is to achieve corrective enzymatic 
levels in skeletal muscle, where ERT effects are variable. We stud-
ied the combination of ERT with rhGAA and NB-DNJ in a KO 
mouse model of PD. Mice were treated with oral NB-DNJ at a 
dose of 4.3 mg/kg for 2 days. On the second day, they received a 
single injection of rhGAA at a dose of 40 mg/kg, comparable to 
that used in PD patients. Organs and tissues from mice were har-
vested 48 hours after the injection, GAA activity was assayed, and 
the results were compared to those obtained in animals treated 
with rhGAA alone.
We  observed  a  significantly  improved  enzyme    correction 
in  gastrocnemius  (1.70-fold  increase  as  compared  to  ani-
mals treated with rhGAA alone) and in diaphragm (1.56-fold 
increase)  (Figure  5).  Activities  measured  in  liver  were  high, 
consistent with the reports showing preferential uptake of GAA 
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Figure 3  nB-dnJ improves rhGAA processing. (a) Western-blot (top) 
and quantitative analysis (bottom) of GAA polypeptides in PD1 and PD2 
fibroblasts  extracts,  incubated  with  50 µmol/l  rhGAA  in  the  absence 
(left) or in the presence (right) of 20 µmol/l NB-DNJ. In cells incubated 
with rhGAA in the presence of the chaperone the mature GAA poly-
peptides are more represented. (b) Time course of correction of GAA 
activity in PD1 and PD2 fibroblasts. PD fibroblasts were incubated with 
50 µmol/l rhGAA in the presence (solid line) or absence (dotted line) 
of 20 µmol/l NB-DNJ. Substantial enhancement of GAA correction by 
NB-DNJ is seen after 8–16 hours of incubation, a time consistent with the 
time required for enzyme maturation. GAA, acid α-glucosidase; NB-DNJ, 
N-butyldeoxynojirimycin; PD, Pompe disease.
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Figure 4  nB-dnJ improves rhGAA stability. (a) GAA activity in PD1 (left panel) and PD2 (right panel) fibroblasts. PD fibroblasts were incubated 
with 50 µmol/l rhGAA in the presence (solid line) or in the absence (dotted line) of 20 µmol/l NB-DNJ. After 24 hours, rhGAA was withdrawn from 
the medium and the decline of GAA activity was analyzed at different times (6, 18, and 30 hours). In the cells treated with the chaperone, NB-DNJ 
was kept in the medium. In NB-DNJ-treated cells, the decline of GAA activity was slower. (b) Western blot analysis of GAA in fibroblast homogenates 
treated as above, showing the persistence of mature GAA isoforms after 30 hours in the cells incubated with the chaperone. GAA, hydrolase acid 
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by this organ,22 and also showed significantly increased activity 
(1.47-fold) in animals treated with the combination of ERT and 
NB-DNJ.
chaperones improve ert efficacy in fibroblasts 
from Fabry disease
An important question is whether the enhancement of ERT effi-
cacy  observed  in  PD  cells  using  pharmacological  chaperones 
in combination with rhGAA can be observed in other LSDs for 
which ERT is available.
To  answer  this  question,  we  incubated  fibroblasts  from  a 
patient with Fabry disease with the recombinant α-galactosidase 
(rhGLA, Fabrazyme) used for ERT, in the presence and in the 
absence  of  the  imino  sugar  1-deoxygalactonojirimycin  (DGJ). 
DGJ has been shown to act as a pharmacological chaperone on 
mutated GLA6,26 and the enhancing effect of DGJ on endogenous 
GLA was detectable also in our Fabry disease cell line, with a two-
fold increase from baseline activity.
When Fabry disease fibroblasts were incubated with 5 nmol/l 
rhGLA for 24 hours, enzyme activity was partially corrected with 
a 3.8-fold increase from baseline. Coincubation with rhGLA and 
20 µmol/l DGJ resulted in a 33.7-fold increase from baseline and 
8.9-fold increase from the activity after incubation with rhGLA 
alone, thus indicating that DGJ enhances the efficacy of ERT in 
correcting enzyme activity (Figure 6). This experiment strongly 
supports the hypothesis that the enhancing effect of chaperones on 
wild-type recombinant enzyme used for ERT is not just limited to 
rhGAA and PD. In contrast, NB-DNJ had no effect on rhGLA effi-
cacy, thus indicating that the enhancing effect of pharmacological 
chaperones requires specific interactions with lysosomal enzymes.
dIscussIon
We  have  demonstrated  that  the  pharmacological  chaperone 
NB-DNJ improves the efficacy of ERT with rhGAA in fibroblasts 
from PD patients and in a mouse model of the disease. Improving 
the efficacy of ERT has great clinical relevance, as it is becoming 
increasingly evident that this therapeutic approach, albeit highly 
successful in some LSDs such as Gaucher disease, has limitations 
in other lysosomal disorders. Specifically, in PD, ERT shows vari-
able efficacy in reverting the skeletal muscle cell pathology typi-
cal of this disorder. Several factors affect the effectiveness of ERT 
in skeletal muscle. These include disease duration and the age at 
start of treatment, the degree of ultrastructural changes in muscle 
fibers and the time required to remodel their architecture, the 
preferential uptake of rhGAA by liver,22 the different biochemi-
cal response of fast-twitch type 2 muscle fibers due to abnormali-
ties of autophagy,23,38,39 the large mass of skeletal muscle which 
accounts for half of the total body weight, the relative deficiency 
of mannose-6-phosphate receptors in muscle cells.40,41
Not only the targeting to muscle, but also the fate of rhGAA, 
once it has been endocytosed, may be suboptimal in PD. In an ani-
mal model of the disease at least part of the enzyme internalized 
by muscle cells is mistrafficked to inappropriate cell compartments, 
such as areas of autophagic build-up.23,38 These data are consistent 
with the results of studies showing abnormal recycling of the cation-
independent mannose 6-phosphate receptor in cultured PD fibro-
blasts.24 As cation-independent mannose 6-phosphate receptor is 
essential for the uptake of the exogenous enzyme and its delivery 
to the late endosomal/lysosomal compartment, in PD fibroblasts 
rhGAA uptake and trafficking were impaired. The mature forms of 
GAA have increased affinity and activity for glycogen as compared 
to the 110-kd GAA precursor.42,43 Therefore, improving the target-
ing or rhGAA to lysosomes and increasing the amount of mature 
GAA isoforms is an important therapeutic goal in PD. Chaperone 
treatment was effective on both aspects as it improved the delivery 
of rhGAA to the lysosomal compartment, as indicated by colocal-
ization studies of fluorescent rhGAA and LAMP2, and increased the 
amounts of mature GAA polypeptides detectable on a western blot 
analysis. The effects of NB-DNJ on cellular distribution, however, 
varied and were more evident in one of the cell lines studied (PD1, 
from an intermediate patient) suggesting that NB-DNJ effects may 
be variably influenced by genotype, disease severity, and underly-
ing abnormalities of vesicles and membrane protein trafficking.
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Figure 5  nB-dnJ improves GAA enzyme correction by rhGAA in vivo. 
Sixteen-week-old PD knock-out mice were treated with NB-DNJ by oral 
administration at a dose of 4.3 mg/kg for 2 days. On the second day, 
the mice were injected with 40 mg/kg rhGAA. The mice were killed after 
48 hours and GAA activity was assayed in the animal tissues. As a con-
trol KO mice treated with same dose of rhGAA were used. L = liver; 
G = gastrocnemius; D = diaphragm; H = heart. The asterisks indicate 
  statistical  significance  (P  <  0.05).  GAA,  acid  α-glucosidase;  NB-DNJ, 
N-butyldeoxynojirimycin; PD, Pompe disease.
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Figure 6  effect of dGJ and nB-dnJ on GlA activity in Fabry disease 
fibroblasts. GLA activity in Fabry disease fibroblasts cultured for 24 hours 
in the absence and in the presence of DGJ, rhGLA alone, NB-DNJ + rhGLA, 
DGJ + rhGLA. Coadministration of the pharmacological chaperone DGJ 
and rhGLA resulted in a 33.7-fold increase from baseline and 8.9-fold 
increase  from  the  activity  after  incubation  with  rhGLA  alone,  indicat-
ing that DGJ enhances the efficacy of ERT in correcting enzyme activ-
ity. DGJ, 1-deoxygalactonojirimycin; GAA, acid α-glucosidase; NB-DNJ, 
N-butyldeoxynojirimycin; PD, Pompe disease.Molecular Therapy  vol. 17 no. 6 june 2009  969
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The use of pharmacological chaperones has been proposed 
and is being translated in human therapy for the treatment of 
patients with missense mutations, causing altered conformation 
of enzyme proteins that retain their catalytic activity. In PD, the 
combination of in vitro studies32,33 and the analysis of molecular 
surveys of large cohorts of PD patients44–46 may give a figure of 
the fraction of patients amenable to enhancement of endogenous 
enzyme with an estimate of ∼10–15%. This limits the use of phar-
macological chaperone therapy for this purpose to a restricted 
population of patients. However, in this study, we showed that 
pharmacological  chaperones  represent  an  effective  tool  in 
enhancing the efficacy of ERT, which should have implications 
for many patients with PD. Thus, our results greatly expand the 
applications of an EET-based therapy, as an adjuvant therapy, to 
all PD patients on ERT with rhGAA.
The  enhancing  effect  of  chaperones  on  ERT  was  not  only 
restricted to PD. We demonstrated that in another LSD, Fabry 
disease caused by α-galactosidase A deficiency, for which an ERT 
is available47 and approved for clinical use, the combined use of 
pharmacological chaperones and ERT is beneficial and improves 
the level of enzyme correction obtained in cells. The use of phar-
macological chaperones is under investigation for a few LSDs. 
For some of these disorders, for which an ERT-based therapy is 
already available or under development, potential chaperone mol-
ecules are not known. Our results suggest that looking for small 
molecules, that may enhance ERT efficacy, may become highly 
relevant for its potential translation into human therapy. In this 
respect,  high  throughput  screenings  of  chemical  libraries  may 
be a time-effective way to expand the applications of EET–ERT 
combination protocols in LSDs. Also high-throughput screenings 
may help identify chaperones with the best enhancing profile as 
  compared to those already available.
Among the advantages of pharmacological chaperones with 
respect  to  recombinant  enzymes,  their  better  biodistribution 
  profile  is  particularly  important.  NB-DNJ  pharmacokinetics 
and distribution has been studied in rat and wide distribution in 
organs and in the animal carcass has been observed.48 In   tissues 
from an animal model of the disease, we found that chaperone 
coadministration  resulted  in  improved  enzymatic  levels  in  a 
skeletal muscle, gastrocnemius, and diaphragm. In a disease like 
PD, increasing the levels of enzyme correction by ERT in these 
muscles is an important therapeutic goal and may have important 
effects on disease progression, motor impairment, and need for 
invasive ventilation.
High doses of NB-DNJ have been used in other animal mod-
els of LSDs, in which the drug was tested as a substrate reducing 
agent, to reach effective tissue concentrations.5 We chose much 
lower doses for our in vivo studies, as these doses are comparable 
to those recommended for human therapy and because, in princi-
ple, low concentrations of the drug may be sufficient to enhance a 
wild-type exogenous enzyme. Further evaluation of the appropri-
ate NB-DNJ dosing and an extensive study of ERT and chaperone 
coadministration in vivo is required before clinical translation of a 
combined therapeutic protocol.
During the past years, it has become clear that a combination 
of therapeutic approaches for LSDs may be required to address all 
the aspects of these systemic disorders. Some examples include the 
combination of ERT and hematopoietic stem cell transplantation,9 
or substrate reduction therapy and ERT that are being evaluated to 
obtain therapeutic effects in tissues and organs (such as bone and 
cartilage) unresponsive to ERT alone. It has become clear, how-
ever, that the approaches currently available are not able to restore 
health in patients by themselves. In addition, supportive therapies 
(physical therapy, respiratory supports, dietary intervention, sup-
port medications) play a major role in improving patients’ quality 
of life. Our results provide further evidence that a combination 
of ERT with other therapies may result in a synergistic effect and 
may affect significantly on the outcome of patients.
MAterIAls And Methods
Cell lines. Cells from a classic infantile (PD 2; patient 1 in ref. 33), two 
intermediate (PD 1 and PD 3; patients 1 and 2 in ref. 49, respectively) and 
two juvenile (PD 4 and PD 5; cases 3 and 5 in ref. 33, respectively) were 
available in the laboratory of the Department of Pediatrics, University of 
Naples, Italy.
Fibroblasts  from  a  patient  with  Fabry  disease  were  provided  by 
M Filocamo, G Gaslini Institute and Telethon Genetic Biobank Network, 
Genoa, Italy. Normal age-matched control fibroblasts, available in the 
laboratory of the Department of Paediatrics, University of Naples, Italy, 
were studied for comparison.
All cell lines were grown at 37 °C with 5% CO2 in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Grand Island, NY) and 10% fetal bovine 
serum  (Sigma-Aldrich,  St  Louis,  MO),  supplemented  with  100  U/ml 
penicillin and 100 mg/ml streptomycin.
Reagents. NB-DNJ and DGJ were purchased from Sigma-Aldrich. The 
primary antibodies used for immunofluorescence and western blot analy-
sis were antibodies anti-human GAA, kindly provided by Bruno Bembi 
and  Andrea  Dardis  (Udine);  anti-β-actin  mouse  monoclonal  antibody 
(Sigma-Aldrich); anti-human LAMP2 mouse monoclonal antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA). Anti-rabbit and anti-mouse second-
ary antibodies conjugated to Alexa Fluor 488 or 596 were from Molecular 
Probes  (Eugene,  OR);  HRP-conjugated  anti-rabbit  or  anti-mouse  IgG 
(Amersham, Freiburg, Germany).
Labeling of rhGAA was performed using a Protein Labeling Kit and 
Alexa Fluor 546 labeling kit (Molecular Probes). rhGAA (Myozyme) and 
rhGLA were purchased from Genzyme Co (Naarden, the Netherlands).
Uptake of recombinant enzymes and enzyme assays. To study rhGAA 
uptake and correction of GAA activity, PD fibroblasts were incubated with 
different concentrations (0.5, 5, and 50 µmol/l) of rhGAA for 24 hours in 
the absence or in the presence of 20 µmol/l NB-DNJ. The cells were then 
harvested  and  cell  pellets  were  washed  twice  with  phosphate-buffered 
saline, resuspended in water and disrupted by five cycles of freeze-  thawing. 
GAA activity was assayed as described already.33 Protein concentrations 
were  measured  in  total  homogenates  by  the  Bradford  assay  (Biorad, 
Hercules, CA).
To study the time course of GAA correction, PD fibroblasts were 
incubated with 50 µmol/l rhGAA for variable periods (2, 4, 8, 18, and 24 
hours) with or without 20 µmol/l NB-DNJ. At each time point, the cells 
were harvested and GAA assayed in cell homogenates as indicated.
For  GAA  stability  studies,  PD  fibroblasts  were  incubated  with 
50 µmol/l rhGAA for 24 hours with or without 20 µmol/l NB-DNJ. rhGAA 
was then removed from the medium, the cells were washed twice with 
phosphate-buffered saline and then harvested at different times (6, 18, 
and 30 hours). In the cells treated with the chaperone NB-DNJ incubation 
was continued during the chase period.
To study the uptake of GLA in Fabry disease fibroblasts, the cells were 
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DGJ, with DGJ alone, with rhGLA and 20 µmol/l NB-DNJ. GLA activity 
was  assayed  by  using  the  fluorogenic  substrate  4-methylumbelliferyl-
α-D-galactopyranoside  (Sigma-Aldrich).  Twenty-five  micrograms  of 
protein were incubated with 3 mmol/l concentrations of substrate and 
0.1 M N-acetyl-D-galactosamine in 0.2 mmol/l acetate buffer, pH 4.5, for 
60 minutes in incubation mixtures of 300 μl. The reaction was stopped by 
adding 700 μl of glycine-carbonate buffer, pH 10.7. Fluorescence was read 
at 365 nm (excitation) and 450 nm (emission) on a Turner Biosystems 
Modulus fluorometer.
Western blot analysis. To study GAA processing, fibroblast extracts were 
subjected to western blot analysis. The cells were harvested, washed in phos-
phate-buffered saline, resuspended in water, and disrupted by five cycles of 
freeze-thawing. Equal amounts (20 μg protein) of fibroblast extracts were 
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (7 or 
10% acrylamide in different experiments) and proteins were transferred to 
PVD membrane (Millipore, Billerica, MA). Anti-human GAA were used as 
primary antibodies to detect GAA polypeptides; to detect β-actin, a mono-
clonal mouse antibody was used. Immunoreactive proteins were detected by 
chemiluminescence (ECL, Amersham, Freiburg, Germany). Quantitative 
analysis of band intensity was performed using ImageJ.
Confocal microscopy analysis. To study the distribution of GAA, LAMP2, 
PD fibroblasts grown on coverslips were fixed using methanol, permeabi-
lized using 0.1% saponin and blocked with 0.01% saponin, 1% fetal bovine 
serum diluted in phosphate-buffered saline for 1 hour. The cells were incu-
bated with the primary antibodies, with secondary antibodies in blocking 
solution and then mounted with vectashield mounting medium (Vector 
Laboratories, Burlingame, CA).
Samples were examined with a Zeiss LSM 5 10 laser scanning confocal 
microscope. We used Argon/2 (458, 477, 488, and 514 nanometers) and 
HeNe1  (543  nanometers)  excitation  lasers,  which  were  switched-on 
separately to reduce crosstalk of the two fluorochromes. The green and the 
red emissions were separated by a dichroic splitter (FT 560) and filtered 
(515–540-nm bandpass filter for green and >610-nm long pass filter for 
red emission). A threshold was applied to the images to exclude ∼99% of 
the signal found in control images. The weighted colocalization coefficient 
represents the sum of intensity of colocalizing pixels in channels 1 and 2 
as compared to the overall sum of pixel intensities above threshold. This 
value could be 0 (no colocalization) or 1 (all pixels colocalize). Bright 
pixels contribute more than faint pixels. The colocalization coefficient in 
Figure 2 represents the weighted colocalization coefficients of Ch1 (red) 
with respect to Ch2 (green) for each experiment.
In vivo experiments. A KO PD mouse model obtained by insertion of neo 
into the Gaa gene exon 650 was purchased from Charles River Laboratories 
(Wilmington, MA) and maintained at the Cardarelli Hospital’s Animal 
Facility (Naples, Italy), in accordance with the Italian Ministry of Health 
regulation. Mice received NB-DNJ (4.3 mg/kg), dissolved in 0.5 ml saline, 
administered daily by gavage for 2 days (treated group), or with 0.5 ml 
saline (control group). On the second day, the animals were injected into 
the tail vein with rhGAA at a dose of 40 mg/kg. The animals were killed 
after 48 hours, the different tissue were harvested, homogenized, and GAA 
activity was measured as indicated above. Each group of mice was com-
posed of three 16-week-old animals. Statistical analysis of GAA activity in 
mouse tissues was performed by the Mann–Whitney test.
suPPleMentArY MAterIAl
Table  S1.  Phenotype,  genotype,  and  residual  GAA  activity  in  PD 
fibroblasts.
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